Charles River Laboratories International, Inc. Common Stock (CRL)
260.72
+26.60 (11.36%)
NYSE· Last Trade: Aug 5th, 5:56 PM EDT
Detailed Quote
Previous Close
234.12
Open
267.99
Bid
255.00
Ask
263.00
Day's Range
252.07 - 267.99
52 Week Range
144.26 - 242.73
Volume
1,780,613
Market Cap
13.14B
PE Ratio (TTM)
-89.90
EPS (TTM)
-2.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
831,682
Chart
About Charles River Laboratories International, Inc. Common Stock (CRL)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively. Read More
Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 2.7% year...
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting results this Wednesday before the bell. Here’s what to look for. Charles River L...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:00 a.m. ET.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks that produce reagents used in the ALA-101 manufacturing process.
Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P...
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.
Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 9:55 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laborato...
